

November 2020

Important EPO News: EPO changes oral proceedings regime to video only

- advantage for all parties involved

**EPO Prosecution Guide:** 

How to achieve a favorable scope of protection and broaden the scope

of protection of early patent filings

EU Case Law News: Supplementary Protection Certificate (SPC):

- how to argue against Royalty Pharma (C-650/17) and TEVA (C-217/17)

The Start-Up Experts: WaHe-patent provides 360° IP services for early and grown up start-ups

**WAGNER + HELBIG** 

Patentanwälte

Conseils en Propriété Intellectuelle
Intellectual Property Counselors

Germany – Switzerland

www.wahe-patent.com © 2020 WaHe patent



November 2020

## **Important EPO news:**

# EPO changes oral proceedings regime to video only

According to new EPC Rules *ex parte* and *inter partes* oral proceedings shall be held by video conference only triggered by the COVID 19 crisis:

We advocate this initiative as it

- saves travel cost
- makes proceedings more efficient for law firms
- makes it easier for clients to participate in hearing
- is technically easy, reliable and convenient
- EPO boards have proven to be capable of correct handling Attending the hearing in person remains a possible option in special cases

link: https://www.epo.org/news-events/news/2020/20200519.html



November 2020

## **EPO Prosecution Guide:**

How to achieve a favorable scope of protection and broaden the scope of protection of early patent filings for an IP value increase

- Pursue a reasonable scope of protection covering the basic invention and your product = original inventive idea
- > Broaden out with more general terms said original inventive idea in 1<sup>st</sup> line divisional application = general inventive idea
- ➤ Broaden out scope of protection to cover competitor products in 2<sup>nd</sup> line divisional application = offensive tool



November 2020

SPC I/III

## **Supplementary Protection Certificate:**

- how to successfully argue against Royalty Pharma and TEVA

## TEVA (C-121/17) major message

- > Important Article: Article 3(a) of Regulation No 469/2009 EU
- ➤ Message: "a product ... is 'protected by a basic patent in force' ... even if ... the ... product ... is not expressly mentioned in the claims of the basic patent, those claims relate necessarily and specifically to that product ..."



November 2020

SPC II/III

#### Supplementary Protection Certificate:

- how to successfully argue against Royalty Pharma and TEVA

#### Royalty Pharma (C-650/17) major message

- > Important Article: Article 3(a) of Regulation No 469/2009 EU
- ➤ Message: "a product is protected by a basic patent ... if it corresponds to a general functional definition ... of the claims ... and necessarily comes within the scope of the invention ... but is not otherwise indicated in individualised form ... provided that it is specifically identifiable, in the light of all the information disclosed by that patent, by a person skilled in the art, based on that person's general knowledge in the relevant field at the filing date or priority date of the basic patent and on the prior art at that date ..."
- "… a product is not protected by a basic patent … , if, although it is covered by the functional definition … in the claims … If it was developed after the filing date of the application for the basic patent, following an independent inventive step …"



November 2020

SPC III/III

#### **Supplementary Protection Certificate:**

- how to successfully argue against Royalty Pharma and TEVA

#### The obstacles:

- > Functional claim language with broad scope of protection
- > Compound is not individualized in the description of basic patent

#### A successful line of argumentation:

- ➤ Align Marketing Authorization compound with disclosure
- > Show hints to specific molecular changes in disclosure
- > Back-up disclosure hints with scientific literature dated before priority date
- > Emphasize state-of-the art, general knowledge and granting practice of priority time
- > Request oral hearing with Examiner before PTO takes decision

WAGNER + HELBIG IP Counselors have successfully represented and counseled clients in pan-EU SPC cases



IP Law Update

November 2020

## WaHe-patent the start-up IP expert of 1st choice

#### **WAGNER + HELBIG provide 360° IP services for start-ups**

We cover of all IP related areas: drafting, prosecution, contracts, trademarks, lean admin organization

Our service approach is based on direct communication and lean organization

#### **WAGNER + HELBIG provide goal-oriented IP services for start-ups**

Our patent drafting and prosecution is budget effective Our IP services focus on start-up needs Our IP services address investor and fund raising needs We understand the venture and IPO language

WAGNER + HELBIG IP Counselors have successfully supported clients' on the IP side which led to >\$150 Mio venture financing and IPOs



# **WAGNER + HELBIG**

Patentanwälte
Conseils en Propriété Intellectuelle
Intellectual Property Counselors

Germany - Switzerland

Germany +49 89 211 87120 Switzerland +41 22 362 4260 helbig@wahe-patent.com

www.wahe-patent.com

Disclaimer: This communication is intended for general information purposes and as a service to clients and friends of WAGNER + HELBIG Patentanwälte. This communication should not be construed as legal advice or a legal opinion on any specific facts or circumstances, nor does it claim completeness of the described cases and it does not create an attorney-client relationship.